James D. Griffin

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Doriano Fabbro, Paul Manley, D. Fabbro, 2002, Cancer cell.

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

P. Atadja, E. Weisberg, S. Remiszewski, 2004, Leukemia.

Drug resistance in mutant FLT3-positive AML

M. Sattler, E. Weisberg, A. Ray, 2010, Oncogene.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

D. Fabbro, D. Neuberg, J. Kutok, 2003, Cancer cell.

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

G. Freeman, J. Griffin, U. Matulonis, 1996, Journal of immunology.

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

J. Griffin, E. Weisberg, James D. Griffin, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Role of B7-1 in mediating an immune response to myeloid leukemia cells.

G. Freeman, J. Griffin, U. Matulonis, 1995, Blood.

Smac mimetics: implications for enhancement of targeted therapies in leukemia

D. Porter, L. Zawel, A. Christie, 2010, Leukemia.

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression

A. Azab, F. Azab, I. Ghobrial, 2013, Leukemia.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

X. Liu, M. Eck, J. Griffin, 2016, Leukemia.